country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-P992158

Copy Link Print Information

VBI-009

VBI-009 is a CD47 and B7-H3 (CD276) bispecific antibody. VBI-009 blocks CD47-SIRPα 'don't eat me' signals and restricts activity to CD47⁺/B7-H3⁺ cells. VBI-009 induces antibody-dependent cellular phagocytosis (ADCP) and antibody-dependent cellular cytotoxicity (ADCC) in CD47⁺/B7-H3⁺ tumor cells. VBI-009 inhibits tumor growth in CD47+/B7-H3+ lung cancer xenograft models. VBI-009 can be used for the research of lung cancer.

For research use only. We do not sell to patients.

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

VBI-009 Chemical Structure

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Species Reactivity
- In Vitro
- In Vivo
- Gene ID
- Accession
- Target
- Conjugated
- Reconsititution
- Format
- Application
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

Species Reactivity

Human

In Vitro

VBI-009 selectively binds to CD47⁺/B7-H3⁺ tumor cells, shows minimal to no binding to B7-H3-negative cells, and does not bind significantly to human red blood cells^[1].
VBI-009 potently blocks the CD47/SIRPα axis on CD47⁺/B7-H3⁺ tumor cells, with minimal to no activity on B7-H3-negative cells^[1].
VBI-009 drives potent antibody-dependent cellular phagocytosis of CD47⁺/B7-H3⁺ tumor cells, with minimal to no activity on B7-H3-negative cells^[1].
VBI-009 drives potent antibody-dependent cellular cytotoxicity of CD47⁺/B7-H3⁺ tumor cells, with minimal to no activity on B7-H3-negative cells^[1].
VBI-009 does not induce hemagglutination of human red blood cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

BI-009 inhibits tumor growth in CD47⁺/B7-H3₊ lung cancer xenograft models^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Gene ID

80381 [NCBI] & 16423 [NCBI]

Accession

Q5ZPR3 & Q61735-1

Target

B7-H3/CD276 & CD47

Conjugated

Unconjugated

Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.

Format

Product Image

Application

ELISA, FACS, Functional assay

Chemical Information

Formulation

Please refer to the lot-specific COA for specific buffer information.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Inhibitory Antibodies User Guide (603 KB)

References

[1]. Wang X, et al. 516 CD47 x B7-H3 bispecific antibody offers a new strategy for treating B7-H3+/CD47+ tumors[J]. 2023.

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote